EDG
Evidence Grade E — Very limited evidence. 1 published studies. 0 registered clinical trials.
Chonluten is a synthetic tripeptide from the Khavinson bioregulator programme, proposed to target bronchial and respiratory tissue. No human clinical trials have been conducted and it has no regulatory approval. One Western-collaborated cell study has been published, which provides a higher evidence standard than most Khavinson compounds.
1 published studies: 1 human, 0 animal, 1 in-vitro, 0 reviews
Chonluten has no marketing authorisation from any major regulatory agency. No human clinical trials have been conducted. The evidence base consists of cell culture studies, including one Western-collaborated publication.
The Western-collaborated study represents a higher standard of evidence than many Khavinson bioregulator publications, but remains a single in vitro study without clinical confirmation. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Chonluten may normalise bronchial cell function by regulating genes related to inflammation and antioxidant activity. A Western-collaborated publication using human monocytic cells reported activation of specific signalling pathways. These observations have not been confirmed through clinical studies.
Research suggests a 2022 study involving Western collaborating institutions reported signalling pathway activation in human immune cells — a somewhat stronger foundation than most Khavinson peptides. However, the primary respiratory function claims rest entirely on Russian-language publications. No human respiratory function data (spirometry, lung function tests) from controlled studies exist. No pharmacokinetic data have been published. Products from unregulated channels lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
TB-500 has no marketing authorisation from any regulatory agency. No human clinical trials of TB-500 specifically have been conducted. The evidence base relies on animal studies of both TB-500 and its parent molecule thymosin beta-4, which are not pharmacologically equivalent. TB-500 is prohibited by WADA and is known from equine and greyhound racing contexts. Products available through unregulated channels lack pharmaceutical quality assurance. The absence of any human safety or efficacy data means that the compound's effects, risks, interactions, and appropriate dosing in humans are unknown.
ARA-290 (cibinetide) has no marketing authorisation. Phase II trials in sarcoidosis neuropathy showed improvements in corneal nerve fibre density, and a Phase II trial in diabetic neuropathy reported improved metabolic parameters and pain scores. The FDA granted Fast Track designation for sarcoidosis neuropathy. No Phase III trials have been completed. The compound represents an investigational approach to tissue repair that is distinct from existing erythropoietin-based therapies, but its clinical development remains at an early stage.
This entry reflects historical nomenclature for the compound more commonly known as BPC-157. The evidence base, regulatory status, and limitations described for BPC-157 (#81) apply identically to this compound. See compound #81 for the full assessment. No marketing authorisation. No human Phase III trials. No established human dosing or safety profile.
